Quagliana J M, Stephens R L, Baker L H, Costanzi J J
J Clin Oncol. 1984 Apr;2(4):316-9. doi: 10.1200/JCO.1984.2.4.316.
A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. There was one complete remission (2.5%) of greater than 12 months duration; seven partial remissions (17.5%) of two, three, three, four, five, six and eight months duration; 11 with no change (27.5%) of one to 10 months duration; and 21 (52.5%) patients with increasing disease. Toxicity included neutropenia, neurotoxicity, phlebitis and cellulitis at the site of injection, alopecia, fever and chills, myalgias, and gastrointestinal toxicity. It was concluded that vindesine does have activity in some patients with metastatic malignant melanoma. Further studies in previously untreated patients are warranted.
一项针对42例转移性黑色素瘤患者开展的II期研究，使用长春地辛（3毫克/平方米，每7至14天缓慢静脉推注一次）。有1例完全缓解（2.5%），缓解持续时间超过12个月；7例部分缓解（17.5%），缓解持续时间分别为2、3、3、4、5、6和8个月；11例病情无变化（27.5%），持续时间为1至10个月；21例（52.5%）患者病情进展。毒性包括中性粒细胞减少、神经毒性、注射部位静脉炎和蜂窝织炎、脱发、发热和寒战、肌痛以及胃肠道毒性。得出的结论是，长春地辛对部分转移性恶性黑色素瘤患者确实有活性。有必要对未接受过治疗的患者开展进一步研究。
